Jiangdong Xiang

Dr. Jiangdong Xiang

Shanghai General Hospital, Shanghai Jiaotong University School of Medicine

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 October 2023 in Cancer Biology & Therapy
Verified
Journal Article
Open access
SYShimin Yang
Shimin Yang
DZDongmei Zhou
Dongmei Zhou
CZChunxiao Zhang
Chunxiao Zhang
JXJiangdong Xiang
Jiangdong Xiang
XXXiaowei Xi
Xiaowei Xi
RNA methyltransferase nucleolar protein p120 (NOP2), commonly referred to as NOP2/Sun RNA methyltransferase family member 1 (NSUN1), is involved in cell proliferation and is highly expressed in various cancers. However, its role in high-grade serous ovarian cancer (HGSOC) remains unclear. Our study investigated the expression of NOP2 in HGSOC tissues and normal fimbria tissues, and found that NOP2 was significantly upregulated in HGSOC tissues. Our experiments showed that NOP2 overexpression promoted cell proliferation in vivo and in vitro and increased the migration and invasion ability of HGSOC cells in vitro. Furthermore, we identified Rap guanine nucleotide exchange factor 4 (RAPGEF4) as a potential downstream target of NOP2 in HGSOC. Finally, our findings suggest that the regulation of NOP2 and RAPGEF4 may depend on m5C methylation levels.

30 August 2021 in BMC Cancer
Verified
Journal Article
Open access
PDF file
RSRongjia Su
Rongjia Su
CJChengjuan Jin
Chengjuan Jin
LZLina Zhou
Lina Zhou
YCYannan Cao
Yannan Cao
MKMenghua Kuang
Menghua Kuang
JXJiangdong Xiang
Jiangdong Xiang
Background: Ovarian cancer is the leading cause of death among gynecological malignancies. Immunotherapy has demonstrated potential effects in ovarian cancer. However, few studies on immune-related prognostic signatures in ovarian cancer have been reported. This study aimed to identify hub genes associated with immune infiltrates to provide insight into the immune regulatory mechanisms in ovarian cancer. Methods: Raw data and clinical information were downloaded from The Cancer Genome Atlas (TCGA) and University of California, Santa Cruz (UCSC) Xena websites. Single-sample gene set enrichment analysis (ssGSEA) and weighted gene co-expression network analysis (WGCNA) were used to identify hub genes. Kaplan-Meier analysis and differential expression analysis were applied to explore the real hub genes. Results: Through ssGSEA and WGCNA, 7 hub genes (LY9, CD5, CXCL9, IL2RG, SLAMF1, SLAMF6, and SLAMF7) were identified. Finally, LY9 and SLAMF1 were recognized as the real hub genes in immune infiltrates of ovarian cancer. LY9 and SLAMF1 are classified as SLAM family receptors involved in the activation of hematopoietic cells and the pathogenesis of multiple malignancies. Furthermore, 12 lncRNAs and 43 miRNAs significantly related to the 2 hub genes were applied to construct a lncRNA-miRNA-mRNA ceRNA network. The lncRNA-miRNA-mRNA ceRNA network shows upstream regulatory sites of the 2 hub genes. Conclusions: These findings improve our understanding of the regulatory mechanism of and reveal potential immune checkpoints for immunotherapy for ovarian cancer.

1 February 2021 in Translational Cancer Research
Verified
Journal Article
Open access
PDF file
RSRongjia Su
Rongjia Su
CJChengjuan Jin
Chengjuan Jin
CJChengwen Jin
Chengwen Jin
MKMenghua Kuang
Menghua Kuang
JXJiangdong Xiang
Jiangdong Xiang
Background: Ovarian cancer is one of the most lethal malignant gynecologic tumors worldwide. We aimed to identify critical hallmarks of the surface epithelium between normal ovaries and serous ovarian carcinomas and then obtain the hub genes associated with these critical hallmarks. Methods: We chose GSE36668, GSE54388 and GSE69428 as data sources and then determined the common gene sets through gene set enrichment analysis (GSEA) to explore essential hallmarks and hub genes driving normal ovarian cells to evolve progressively into a neoplastic state. The differentially expressed genes (DEGs) extracted separately in each gene set were analyzed again through the Metascape website. Kaplan-Meier plotter was used to obtain significant prognostic information. The hub genes were obtained through protein-protein interaction (PPI) network by Cytoscape. Hub genes were confirmed to have higher mRNA and protein expression levels in ovarian cancer tissues than in normal tissues through public databases [Gene Expression Profiling Interactive Analysis (GEPIA) and The Human Protein Atlas]. Correlation analysis of six hub genes showed a strong correlation via R. Results: We obtained 11 common hallmarks from GSEA of the three mentioned datasets and 22 hub genes that showed a significant association with poor survival. Conclusions: Not only the gene sets enriched by GSEA but also the hub genes extracted by the PPI network indicate that the most fundamental trait of ovarian cancer cells involves their ability to sustain chronic proliferation.

19 November 2021 in Frontiers in Molecular Biosciences
Verified
Journal Article
Open access
RSRongjia Su
Rongjia Su
YLYuan Liu
Yuan Liu
XWXiaomei Wu
Xiaomei Wu
JXJiangdong Xiang
Jiangdong Xiang
XXXiaowei Xi
Xiaowei Xi
Background: The homologous recombination (HR) pathway defects in cancers induced abrogation of cell cycle checkpoints, resulting in the accumulation of DNA damage, mitotic catastrophe, and cell death. Cancers with BRCA1/2 loss and other accumulation of similar genomic scars resulting in HRD displayed increased sensitivity to chemotherapy. Our study aimed to explore HRD score genetic mechanisms and subsequent clinical outcomes in human cancers, especially ovarian cancer.Methods: We analyzed TCGA data of HRD score in 33 cancer types and evaluated HRD score distribution and difference among tumor stages and between primary and recurrent tumor tissues. A weighted gene co-expression network analysis (WGCNA) was performed to identify highly correlated genes representing essential modules contributing to the HRD score and distinguish the hub genes and significant pathways. We verified HRD status predicting roles in patients’ overall survival (OS) with univariate and multivariate Cox regression analyses and built the predicting model for patient survival.Results: We found that the HRD score increased with the rise in tumor stage, except for stage IV. The HRD score tended to grow up higher in recurrent tumor tissue than in their primary counterparts (p = 0.083). We constructed 15 co-expression modules with WGCNA, identified co-expressed genes and pathways impacting the HRD score, and concluded that the HRD score was tightly associated with tumor cells replication and proliferation. A combined HRD score ≥42 was associated with shorter OS in 33 cancer types (HR = 1.010, 95% CI: 1.008–1.011, p < 0.001). However, in ovarian cancer, which ranked the highest HRD score among other cancers, HRD ≥42 cohort was significantly associated with longer OS (HR = 0.99, 95% CI: 0.98–0.99, p < 0.0001). We also built a predicting model for 3 and 5 years survival in HGSC patients.Conclusion: A quantitative HRD score representing the accumulated genomic scars was dynamically increasing in proliferating tumor cells since the HRD score was tightly correlated to tumor cell division and replication. We highlighted HRD score biomarker role in prognosis prediction of ovarian cancer.

26 May 2025 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
LHLi Juan Huang
Li Juan Huang
FCFeng Chen
Feng Chen
LCLin Chen
Lin Chen
SZShi Tong Zhan
Shi Tong Zhan
MLMing Min Liu
Ming Min Liu
YYYe Yang
Ye Yang
Background: Gasdermin D (GSDMD), a key executor of pyroptosis, has been implicated in modulating the tumor immune microenvironment. However, its role as a predictive biomarker for immunotherapy response remains unclear.Methods: We conducted a pan-cancer analysis of GSDMD expression across TCGA datasets and investigated its association with tumor mutational burden (TMB), microsatellite instability (MSI), and mismatch repair (MMR) status. Immunological relevance was further assessed by correlating GSDMD expression with immune cell infiltration and immune checkpoint gene signatures. We performed single-cell RNA sequencing analysis to investigate the immune cell populations and immunological pathways associated with GSDMD expression. Finally, organoid-based functional assays confirmed that Poly ADP-ribose polymerase inhibitors (PARPi) exert antitumor effects at least in part by enhancing GSDMD-mediated pyroptosis.Results: GSDMD was found to be aberrantly expressed in multiple tumor types and positively correlated with TMB, MSI, and immune checkpoint expression. High GSDMD expression was associated with increased infiltration of pro-inflammatory immune cells. In organoid models, GSDMD expression influenced sensitivity to PARPi, suggesting a potential role in shaping the immune-responsive phenotype.Conclusion: Our findings highlight GSDMD as a potential biomarker for predicting immunotherapy response and as a modulator of tumor-immune interactions. These results provide a foundation for future studies exploring GSDMD-targeted strategies to enhance immunotherapeutic efficacy.

16 February 2026 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
LZLina Zhou
Lina Zhou
RWRencheng Wang
Rencheng Wang
GDGuiqiang Du
Guiqiang Du
YWYupeng Wu
Yupeng Wu
HLHui Li
Hui Li
JXJiangdong Xiang
Jiangdong Xiang
Background: Apolipoproteins (APOs) are essentially structural and functional components of lipoproteins, which are composed of 22 members and their effects on certain types of cancer have been studied. However, their roles in endometrial cancer (EC), which is one of the most common malignant tumors in gynecology were unclear and rarely investigated. Methods: We investigated the expression levels of APOs genes in EC. Furthermore, we explored the roles of APOs in prognostic value, and immune infiltrates in EC patients by using different bioinformatics databases. In-vitro experiments were also conducted to evaluate the effect of APOs genes expression on migrant abilities of EC cells. Results: Nine APO genes (APOC1, APOC2, APOC4, APOD, APOE, APOL3, APOL4, APOLD1, and APOO) were found differently expressed between EC and control tissues by the GEPIA2. However, APOC4 was not included in the subsequent analysis due to its low expression in EC tissues. Moreover, mRNA expression levels of APOs were found correlated with the clinicopathological characteristics of EC, including stage, grade, molecular subgroups, p53 mutant conditions, PTEN mutant conditions, and expression levels of ESR1 and ESR2. Meanwhile higher expression levels of APOs were significantly correlated with better (APOD, APOL3) or poorer (APOC1, APOE, APOLD1) OS. ssGSEA showed 7 TILs in EC which differed significantly from those in adjacent noncancerous tissues were correlated with prognosis of EC patients. The expression levels of both APOD and APOE were positively correlated with all 7 TILs. Finally, western blotting showed that 17β-estradiol (E2) increased APOE protein expression level and reduced APOD protein expression level. Furthermore, APOE was identified to promote the cell migration by scratch assay. Conclusion: The expression of APOs may be a promising prognostic biomarker and is associated with immune invasion as a potential target for endometrial cancer.